ABG Management Ltd. (10% owner) acquired 700,741 shares of PMN at $12.13 for $8,499,988.33; holdings surged 289.1% to 943,090 shares
ABG Management Ltd., already a 10% owner, deployed $8,499,988.33 to purchase 700,741 shares at $12.13, dramatically expanding its stake from 242,349 shares to 943,090 shares in a single transaction. The stock has recovered 70.4% over 30 days and 38.3% over 90 days from recent lows, but remains 53.2% below its 52-week high of $28.00, suggesting the purchase occurred in a recovery phase but still well below peak valuation. The company is unprofitable (net income of $-11,580,126.00) and trades at a P/E of 119.09 with a market cap of $704,925,541.00, indicating this is a speculative or turnaround story rather than a mature profitable enterprise. This near-tripling of an anchor shareholder's position in an unprofitable biotech signals substantial conviction in future value creation, though the absence of profitability means investors must carefully evaluate whether the recovery trajectory and pipeline justify the concentrated exposure now being assumed.